As of June 21, 2025, ALX Oncology Holdings Inc (ALXO) reports a Net Margin of -3876.27%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of ALX Oncology Holdings Inc's Net Margin
Over recent years, ALX Oncology Holdings Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -3876.27% |
| 2023-12-31 | -3876.27% |
| 2022-12-31 | -400.83% |
| 2021-12-31 | -663.29% |
This slight upward trend highlights how ALX Oncology Holdings Inc manages its overall profitability and cost control over time.
Comparing ALX Oncology Holdings Inc's Net Margin to Peers
To better understand ALX Oncology Holdings Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| ALX Oncology Holdings Inc (ALXO) | -3876.27% |
| Regeneron Pharmaceuticals Inc (REGN) | 31.07% |
| Amgen Inc (AMGN) | 12.24% |
| Abbvie Inc (ABBV) | 7.59% |
| Gilead Sciences Inc (GILD) | 1.67% |
| Ligand Pharmaceuticals Inc (LGND) | -2.41% |
Compared to its competitors, ALX Oncology Holdings Inc's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.